# Dapagliflozin at Discharge on Hospital Heart Failure Readmission

Study · id `cardio:ct-nct04249778` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04249778](<https://clinicaltrials.gov/study/NCT04249778>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04249778

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT04249778. Randomized; double masking; primary purpose treatment. Start 2020-07-29 (actual); primary completion 2022-03-03 (actual). Results posted on 2023-03-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT04249778, source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)
- Started: 2020-07-29 (actual) (ClinicalTrials.gov record NCT04249778, source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)
- Primary completion: 2022-03-03 (actual) (ClinicalTrials.gov record NCT04249778, source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)
- Completion: 2022-03-03 (actual) (ClinicalTrials.gov record NCT04249778, source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)
- Results first posted: 2023-03-29 (ClinicalTrials.gov record NCT04249778, source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04249778, source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04249778-2024-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin at Discharge on Hospital Heart Failure Readmission
- Condition: Heart Failure
- Condition: Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Emory University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)

## Provenance

Content hash: ca42047d42bced22a4a87e3fef4047b09cc42bd73baf9940f74b33ff040648da
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
